Three participants experienced AEs attributed to the study product by the investigator: 1 participant had increased alanine aminotransferase (severe); 1 participant had increased alanine aminotransferase (mild), increased aspartate aminotransferase (mild) and dermatitis (mild); 1 participant had rash (moderate) and rash maculo-papular (moderate); all resolved by the end of the trial. This evidence concerns the gene GPT and dermatitis.